HOME >> MEDICINE >> NEWS
Researchers identify brain pathway to explain how Fenfluramine causes weight loss

BOSTON Scientists have identified the molecular pathway in the brain that helps explain how the once-popular diet drug d-Fenfluramine (d-FEN) works to promote weight loss, a discovery reported in the July 26 issue of Science that could provide an opportunity to develop a new anti-obesity treatment without d-FEN's cardiac side effects.

The study, led by a team of researchers at Beth Israel Deaconess Medical Center (BIDMC), also suggests this same brain pathway the melanocortin system is responsible for regulation of body weight at either end of the weight spectrum from obesity at one extreme to anorexia nervosa at the other.

D-FEN, used in combination with phenteramine and known as fen-phen, was banned by the U.S. Food and Drug Administration (FDA) in 1997 after a subset of patients taking the drug developed cardiac complications.

"This study helps close the circle on the role of the melanocortin pathway and adds the serotonin system to the growing list of metabolic signals including leptin that act on the brain's melanocortin neurons, regulating food intake and body weight," explains the study's senior author Joel Elmquist, D.V.M., Ph.D., a neuroscientist and endocrinologist at BIDMC and associate professor of endocrinology and medicine at Harvard Medical School.

The diet drug d-FEN, which is the "fen" part of the fen-phen combination, first came on the market in 1992, and within five years, had been prescribed to millions of individuals who were trying to lose weight. The drug works by increasing the brain's release of serotonin, a "chemical messenger" that, among other things, helps to suppress appetite. Serotonin acts as a neurotransmitter to convey nerve impulses in the brain, and anti-obesity drugs such as fenfluramine, as well as the popular antidepressant medications fluoxetine (Prozac) and sertraline (Zoloft) work by enhancing this effect.

However, as Elmquist explains, d-FEN's popularity was relatively brief:
'"/>

Contact: Bonnie Prescott
bprescot@caregroup.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
25-Jul-2002


Page: 1 2 3

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:7/24/2014)... University of Texas at Arlington professor who co-authored ... foundations engaged in community revitalization has been awarded ... 2014., Maria Martinez-Cosio, associate professor in the School ... award this week at the society,s national conference, ... lecturer and academic coordinator in the Urban Studies ...
(Date:7/24/2014)... of contents if you need to know precisely what substances ... to be a highly skilled chemist or to have genuine ... molecular structure of the various substances. Christian Grundahl Frankr, a ... has developed a method that allows him to use X-rays ... ,Fingerprints, of a Substance , The technique is called ,powder ...
(Date:7/24/2014)... 23, 2014 (HealthDay News) -- A growing number of ... to boost their muscles and athletic ability, a new ... admit to using hGH jumped to 11 percent in ... in 2012, the new survey from the Partnership for ... a need for tighter regulation and oversight of performance-enhancing ...
(Date:7/24/2014)... a professional supplier of wedding dresses and special occasion gowns, ... of cheap wedding dresses to its online catalog. ... discounts. According to the CEO of the company, Stwd.co.uk is ... They are available at low rates, up to 55% off. ... previously priced at $150, and it is offered at a ...
(Date:7/24/2014)... 2014 Hayes, Inc. ( http://www.hayesinc.com ), ... use of evidence, is pleased to announce that Dee ... guest speaker at the AHRMM14 Conference in ... expert in value analysis who also serves as the ... Professionals (AHVAP), will facilitate and participate in two preconference ...
Breaking Medicine News(10 mins):Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 2Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 4Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 5Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 3
(Date:7/24/2014)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported ... The Company reported second quarter net sales of $1.18 ... currency over the second quarter of 2013.  Diluted earnings ... $1.49 adjusted, an increase of 4.2% adjusted over the ... was marked by solid sales growth in a number ...
(Date:7/24/2014)... July 24, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro ... measure Carbon Monoxide Diffusing Capacity (DLCO) for phase 2 ... study of Chronic Obstructive Pulmonary Disease (COPD) ever undertaken. ... in the U.S. and affects millions of people worldwide.  ...
(Date:7/23/2014)... 2014 Announced at the 20 th ... agreement seeks to increase access to a promising new HIV ... 2014 conference in Melbourne today, the ... Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine ... in India and China ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
Cached News: